333 related articles for article (PubMed ID: 12738346)
21. Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence.
Schottenfeld RS; Chawarski MC; Pakes JR; Pantalon MV; Carroll KM; Kosten TR
Am J Psychiatry; 2005 Feb; 162(2):340-9. PubMed ID: 15677600
[TBL] [Abstract][Full Text] [Related]
22. Using buprenorphine for outpatient opioid detoxification.
Manlandro JJ
J Am Osteopath Assoc; 2007 Sep; 107(9 Suppl 5):ES11-6. PubMed ID: 17908825
[TBL] [Abstract][Full Text] [Related]
23. Buprenorphine for office-based treatment of patients with opioid addiction.
Manlandro JJ
J Am Osteopath Assoc; 2005 Jun; 105(6 Suppl 3):S8-13. PubMed ID: 16118361
[TBL] [Abstract][Full Text] [Related]
24. Expanding Treatment Opportunities for Hospitalized Patients with Opioid Use Disorders.
Winetsky D; Weinrieb RM; Perrone J
J Hosp Med; 2018 Jan; 13(1):62-64. PubMed ID: 29073311
[TBL] [Abstract][Full Text] [Related]
25. Help Is on the Way: Medicare Coverage of Opioid Treatment Programs.
Felix C; Sharfstein JM; Olsen Y
J Am Geriatr Soc; 2020 Mar; 68(3):637-640. PubMed ID: 31825528
[TBL] [Abstract][Full Text] [Related]
26. Responses among substance abuse treatment providers to the opioid epidemic in the USA: Variations in buprenorphine and methadone treatment by geography, operational, and payment characteristics, 2007-16.
Yang JC; Roman-Urrestarazu A; Brayne C
PLoS One; 2020; 15(3):e0229787. PubMed ID: 32126120
[TBL] [Abstract][Full Text] [Related]
27. Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis.
Yarborough BJ; Stumbo SP; McCarty D; Mertens J; Weisner C; Green CA
Drug Alcohol Depend; 2016 Mar; 160():112-8. PubMed ID: 26796596
[TBL] [Abstract][Full Text] [Related]
28. Patterns of physician prescribing for opioid maintenance treatment in Ontario, Canada in 2014.
Guan Q; Khuu W; Spithoff S; Kiran T; Kahan M; Tadrous M; Martins D; Leece P; Gomes T
Drug Alcohol Depend; 2017 Aug; 177():315-321. PubMed ID: 28733101
[TBL] [Abstract][Full Text] [Related]
29. Diversion and injection of methadone and buprenorphine among clients in public opioid treatment clinics in New South Wales, Australia.
Winstock AR; Lea T
Subst Use Misuse; 2010; 45(1-2):240-52. PubMed ID: 20025451
[TBL] [Abstract][Full Text] [Related]
30. Reframing the Prevention Strategies of the Opioid Crisis: Focusing on Prescription Opioids, Fentanyl, and Heroin Epidemic.
Manchikanti L; Sanapati J; Benyamin RM; Atluri S; Kaye AD; Hirsch JA
Pain Physician; 2018 Jul; 21(4):309-326. PubMed ID: 30045589
[TBL] [Abstract][Full Text] [Related]
31. Challenges and Opportunities for the Use of Medications to Treat Opioid Addiction in the United States and Other Nations of the World.
Parrino MW; Maremmani AG; Samuels PN; Maremmani I
J Addict Dis; 2015; 34(2-3):255-62. PubMed ID: 26110357
[TBL] [Abstract][Full Text] [Related]
32. The US Opioid Crisis: Current Federal and State Legal Issues.
Soelberg CD; Brown RE; Du Vivier D; Meyer JE; Ramachandran BK
Anesth Analg; 2017 Nov; 125(5):1675-1681. PubMed ID: 29049113
[TBL] [Abstract][Full Text] [Related]
33. Opioid drugs in maintenance and detoxification treatment of opiate addiction; addition of buprenorphine and buprenorphine combination to list of approved opioid treatment medications. Interim final rule.
Substance Abuse and Mental Health Services Administration (SAMHSA), Department of Health and Human Services
Fed Regist; 2003 May; 68(99):27937-9. PubMed ID: 12762334
[TBL] [Abstract][Full Text] [Related]
34. Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence.
Ridge G; Gossop M; Lintzeris N; Witton J; Strang J
J Subst Abuse Treat; 2009 Jul; 37(1):95-100. PubMed ID: 19004598
[TBL] [Abstract][Full Text] [Related]
35. Perioperative Considerations for the Patient with Opioid Use Disorder on Buprenorphine, Methadone, or Naltrexone Maintenance Therapy.
Harrison TK; Kornfeld H; Aggarwal AK; Lembke A
Anesthesiol Clin; 2018 Sep; 36(3):345-359. PubMed ID: 30092933
[TBL] [Abstract][Full Text] [Related]
36. New federal regulations for improving quality in opioid treatment programs.
Pelletier LR; Hoffman JA
J Healthc Qual; 2001; 23(6):29-34. PubMed ID: 23413476
[TBL] [Abstract][Full Text] [Related]
37. From methadone to buprenorphine: changes during a 10 year period within a national opioid maintenance treatment programme.
Riksheim M; Gossop M; Clausen T
J Subst Abuse Treat; 2014 Mar; 46(3):291-4. PubMed ID: 24210532
[TBL] [Abstract][Full Text] [Related]
38. What the X? Understanding changes in buprenorphine prescribing regulation.
Speight C
J Am Assoc Nurse Pract; 2024 Mar; 36(3):147-150. PubMed ID: 37646580
[TBL] [Abstract][Full Text] [Related]
39. One size does not fit all-evolution of opioid agonist treatments in a naturalistic setting over 23 years.
Nordt C; Vogel M; Dey M; Moldovanyi A; Beck T; Berthel T; Walter M; Seifritz E; Dürsteler KM; Herdener M
Addiction; 2019 Jan; 114(1):103-111. PubMed ID: 30209840
[TBL] [Abstract][Full Text] [Related]
40. Intravenous misuse of buprenorphine: characteristics and extent among patients undergoing drug maintenance therapy.
Moratti E; Kashanpour H; Lombardelli T; Maisto M
Clin Drug Investig; 2010; 30 Suppl 1():3-11. PubMed ID: 20450240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
